Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children

被引：46

作者：

Chovatiya, Raj ^{[1
]}

Silverberg, Jonathan, I ^{[2
]}

机构：

[1] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA

[2] George Washington Univ, Dept Dermatol, Sch Med, Washington, DC 20037 USA

来源：

CHILDREN-BASEL | 2019年 / 6卷 / 10期

基金：

美国国家卫生研究院;

关键词：

atopic dermatitis; psoriasis; inflammation; cytokine; skin-barrier; topical therapy; systemic therapy; biologic therapy; SEVERE PLAQUE PSORIASIS; JANUS KINASE INHIBITOR; PHOSPHODIESTERASE-4; PDE4; INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; STRATUM-CORNEUM HYDRATION; LONG-TERM EFFICACY; VITAMIN-D ANALOGS; QUALITY-OF-LIFE; NARROW-BAND UVB;

D O I：

10.3390/children6100108

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.

引用

页数：25

共 240 条

[61] Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials [J].

Gordon, Kenneth B. ;

Strober, Bruce ;

Lebwohl, Mark ;

Augustin, Matthias ;

Blauvelt, Andrew ;

Poulin, Yves ;

Papp, Kim A. ;

Sofen, Howard ;

Puig, Lluis ;

Foley, Peter ;

Ohtsuki, Mamitaro ;

Flack, Mary ;

Geng, Ziqian ;

Gu, Yihua ;

Valdes, Joaquin M. ;

Thompson, Elizabeth H. Z. ;

Bachelez, Herve .

LANCET, 2018, 392 (10148) :650-661

[62] Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials [J].

Gordon, Kenneth B. ;

Papp, Kim A. ;

Langley, Richard G. ;

Ho, Vincent ;

Kimball, Alexa B. ;

Guzzo, Cynthia ;

Yeilding, Newman ;

Szapary, Philippe O. ;

Fakharzadeh, Steven ;

Li, Shu ;

Hsu, Ming-Chun ;

Reich, Kristian .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (05) :742-751

[63] Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) [J].

Gottlieb, Alice B. ;

Blauvelt, Andrew ;

Thaci, Diamant ;

Leonardi, Craig L. ;

Poulin, Yves ;

Drew, Janice ;

Peterson, Luke ;

Arendt, Catherine ;

Burge, Daniel ;

Reich, Kristian .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) :302-+

[64] Psoriasis [J].

Greb, Jacqueline E. ;

Goldminz, Ari M. ;

Elder, James T. ;

Lebwohl, Mark G. ;

Gladman, DafnaD. ;

Wu, Jashin J. ;

Mehta, Nehal N. ;

Finlay, Andrew Y. ;

Gottlieb, Alice B. .

NATURE REVIEWS DISEASE PRIMERS, 2016, 2

[65] Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons [J].

Gregorio, Josh ;

Meller, Stephan ;

Conrad, Curdin ;

Di Nardo, Anna ;

Homey, Bernhard ;

Lauerma, Antti ;

Arai, Naoko ;

Gallo, Richard L. ;

DiGiovanni, John ;

Gilliet, Michel .

JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (13) :2921-2930

[66] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials [J].

Griffiths, Christopher E. M. ;

Reich, Kristian ;

Lebwohl, Mark ;

van de Kerkhof, Peter ;

Paul, Carle ;

Menter, Alan ;

Cameron, Gregory S. ;

Erickson, Janelle ;

Zhang, Lu ;

Secrest, Roberta J. ;

Ball, Susan ;

Braun, Daniel K. ;

Osuntokun, Olawale O. ;

Heffernan, Michael P. ;

Nickoloff, Brian J. ;

Papp, Kim .

LANCET, 2015, 386 (9993) :541-551

[67] Psoriasis: epidemiology [J].

Gudjonsson, Johann E. ;

Elder, James T. .

CLINICS IN DERMATOLOGY, 2007, 25 (06) :535-546

[68] Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis [J].

Guttman-Yassky, Emma ;

Lowes, Michelle A. ;

Fuentes-Duculan, Judilyn ;

Whynot, Julia ;

Novitskaya, Inna ;

Cardinale, Irma ;

Haider, Asifa ;

Khatcherian, Artemis ;

Carucci, John A. ;

Bergman, Reuven ;

Krueger, James G. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (05) :1210-1217

[69] Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study [J].

Guttman-Yassky, Emma ;

Silverberg, Jonathan I. ;

Nemoto, Osamu ;

Forman, Seth B. ;

Wilke, August ;

Prescilla, Randy ;

de la Pena, Amparo ;

Nunes, Fabio P. ;

Janes, Jonathan ;

Gamalo, Margaret ;

Donley, David ;

Paik, Jim ;

DeLozier, Amy M. ;

Nickoloff, Brian J. ;

Simpson, Eric L. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (04) :913-+

[70] Barrier Epithelial Cells and the Control of Type 2 Immunity [J].

Hammad, Hamida ;

Lambrecht, Bart N. .

IMMUNITY, 2015, 43 (01) :29-40

← 2 3 4 5 6 7 8 9 10 11 →